Chong Kun Dang Pharmaceutical (185750) — Cash Flow Reinvestment Rate
Chong Kun Dang Pharmaceutical (185750) has a Cash Flow Reinvestment Rate of 7.60x as of March 2026, reinvesting ₩93.65 Billion (capex ₩74.34 Billion plus investments ₩19.31 Billion) from operating cash flow of ₩12.32 Billion. See free cash flow generation of Chong Kun Dang Pharmaceutical to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Chong Kun Dang Pharmaceutical Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Chong Kun Dang Pharmaceutical across 10 annual periods. For the full cash flow conversion analysis, see 185750 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year capital reinvestment analysis for Chong Kun Dang Pharmaceutical. See Chong Kun Dang Pharmaceutical leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 3.65x | ₩245.91 Billion | ₩67.36 Billion | ₩179.13 Billion | ▲ +73.4% |
| 2024 | 2.11x | ₩135.37 Billion | ₩64.29 Billion | ₩66.10 Billion | ▲ +179.0% |
| 2023 | 0.75x | ₩240.12 Billion | ₩318.16 Billion | ₩68.81 Billion | ▼ -11.4% |
| 2022 | 0.85x | ₩57.70 Billion | ₩67.73 Billion | ₩44.90 Billion | ▼ -87.4% |
| 2021 | 6.79x | ₩87.57 Billion | ₩12.90 Billion | ₩48.24 Billion | ▲ +1078.5% |
| 2020 | 0.58x | ₩60.08 Billion | ₩104.32 Billion | ₩32.64 Billion | ▲ +20.0% |
| 2019 | 0.48x | ₩37.09 Billion | ₩77.29 Billion | ₩21.84 Billion | ▼ -27.3% |
| 2018 | 0.66x | ₩28.12 Billion | ₩42.63 Billion | ₩21.92 Billion | ▲ +134.3% |
| 2017 | 0.28x | ₩23.00 Billion | ₩81.67 Billion | ₩19.79 Billion | ▼ -80.4% |
| 2016 | 1.43x | ₩82.84 Billion | ₩57.79 Billion | ₩39.44 Billion | — |